Subscribe to our newsletter

Corrona announces first patient has enrolled in its Inflammatory Bowel Disease Registry

CorEvitas is now part of Thermo Fisher Scientific. Read More.

SOUTHBOROUGH, Mass., June 1, 2017 /PRNewswire — Corrona, a nationwide provider of disease registries, announced that the first patient has been enrolled in its groundbreaking Inflammatory Bowel Disease (IBD) Registry. No national registry presently collects data from patients with inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. Corrona established strategic partnerships with industry leaders supporting IBD disease therapies. Our partners provide expertise, tools and resources that compliment the research discovery process.

“I am immensely gratified and excited to be working with Corrona to establish this much-needed registry for our patients with inflammatory bowel disease. The IBD Registry represents a greatly valued resource for our patients who suffer with these diseases as well as the gastroenterologists who treat them.” — Dr. Joshua Korzenik, Director of Crohn’s and Colitis Center, Brigham and Women’s Hospital of Harvard Medical School

“We are happy to partner with Corrona to help establish the IBD Registry, which we believe will lead to a better understanding of the natural history of inflammatory bowel disease, associated co-morbidities and the current treatment paradigm.” — Tamas A. Koncz, MD, PhD, Chief Medical Officer, Inflammation and Immunology, Pfizer

Corrona supports a nationwide network of sites contributing to four US registries including the largest registry in the world collecting data on rheumatoid arthritis (RA). The RA registry is also active in Japan. Beginning data collection in 2001, Corrona is one of the oldest functioning registries deriving data on patients with RA. It has expanded to include spondyloarthropathies (including psoriatic arthritis), psoriasis, and now IBD.

Hundreds of peer-reviewed manuscript and abstract publications are produced from Corrona’s registries. Corrona provides real world perspectives on the safety and effectiveness of new and existing agents. A staff of biostatisticians and epidemiologists work on data for publications.


About Corrona
Corrona was founded in 2001 by leading physicians dedicated to advancing and improving the care of patients with chronic autoimmune diseases. Its mission is to advance research and improve the quality of patient care through world-class observational cohorts. Corrona provides longitudinal clinical data, patient reported measures, and research results to biopharmaceutical companies. Corrona data analysis provides a rich framework in which to explore topics such as comparative effectiveness, post market safety reporting, and commercial applications.Read more at

Learn More About IBD
If you are interested in learning more about the Corrona IBD Registry, please contact Corrona by completing a brief online survey using the link below.

Learn More About IBD

For general inquiries questions contact us at or call us at (508) 266-8255.

For Media Requests, please contact: Wendi Malley, MS, Director of Marketing & Product Development (508) 594-8302,